Literature DB >> 17613717

Longitudinal study of two cases of progressive multifocal leukoencephalopathy with a clinical benign evolution.

Serena Delbue1, Enrico Marchioni, Giovanni Sotgiu, Marina Saresella, Eleonora Tavazzi, Elena Colombo, Franca Rosa Guerini, Renato Maserati, Elena Sinforiani, Maria Rita Schifino, Pasquale Ferrante.   

Abstract

Progressive multifocal leukoencephalopathy (PML) usually is a rapid and fatal demyelinating disease of the central nervous system (CNS), caused by JC virus (JCV). After the introduction of Highly active antiretroviral therapy (HAART), its prognosis has been modified in some cases but remains a relevant cause of morbidity in human immunodeficiency virus-seropositive (HIV+) patients. The authors report here two cases of PML, followed over time, sharing a benign course and a JCV antigen-specific T-cell response, but with different cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), and clinical features. In both cases, JCV DNA detection in brain biopsies samples and specific antigenic response preceded its isolation in the CSF by several months. In one patient, during the first stage of the disease, the presence of CSF and MRI inflammatory findings, associated with the lack of JCV detection in the CSF, made the diagnosis more challenging. Given that to date a reformation of the laboratory parameters for PML diagnosis is strongly needed, this report highlights the following considerations: (a) indications for performing brain biopsy in HIV-related leukoencephalopathies of uncertain origin, and (b) the role of JCV immunologically specific T-cell response as an additional marker for PML diagnosis and indicator for good prognosis of the disease.

Entities:  

Mesh:

Year:  2007        PMID: 17613717     DOI: 10.1080/13550280701291796

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  22 in total

Review 1.  Progressive multifocal leukoencephalopathy.

Authors:  J R Berger; E O Major
Journal:  Semin Neurol       Date:  1999       Impact factor: 3.420

2.  Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?

Authors:  S Di Giambenedetto; G Vago; A Pompucci; G Scoppettuolo; A Cingolani; A Marzocchetti; M Tumbarello; R Cauda; A De Luca
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

3.  Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.

Authors:  Simona Bossolasco; Giliola Calori; Francesca Moretti; Antonio Boschini; Davide Bertelli; Maurizio Mena; Simonetta Gerevini; Arabella Bestetti; Rosa Pedale; Serena Sala; Stefania Sala; Adriano Lazzarin; Paola Cinque
Journal:  Clin Infect Dis       Date:  2005-02-01       Impact factor: 9.079

4.  Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy.

Authors:  Angela Marzocchetti; Simona Di Giambenedetto; Antonella Cingolani; Adriana Ammassari; Roberto Cauda; Andrea De Luca
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Human T-cell lymphotropic virus tax and Epstein-Barr virus DNA in peripheral blood of multiple sclerosis patients during acute attack.

Authors:  P Ferrante; E Omodeo-Zorini; M R Zuffolato; R Mancuso; R Caldarelli-Stefano; S Puricelli; M Mediati; L Losciale; D Caputo
Journal:  Acta Neurol Scand Suppl       Date:  1997

6.  A case of a progressive multifocal leukoencephalopathy patient with four different JC virus transcriptional control region rearrangements in cerebrospinal fluid, blood, serum, and urine.

Authors:  Serena Delbue; Giovanni Sotgiu; Daniela Fumagalli; Marilena Valli; Elisa Borghi; Roberta Mancuso; Enrico Marchioni; Renato Maserati; Pasquale Ferrante
Journal:  J Neurovirol       Date:  2005-02       Impact factor: 2.643

7.  Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease.

Authors:  M Clerici; M Saresella; D Trabattoni; L Speciale; S Fossati; S Ruzzante; R Cavaretta; M Filippi; D Caputo; P Ferrante
Journal:  J Neuroimmunol       Date:  2001-12-03       Impact factor: 3.478

8.  Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy.

Authors:  Aurélie Vendrely; Boris Bienvenu; Jacques Gasnault; Jean Baptiste Thiebault; Dominique Salmon; Françoise Gray
Journal:  Acta Neuropathol       Date:  2005-03-01       Impact factor: 17.088

9.  PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy.

Authors:  P Ferrante; R Caldarelli-Stefano; E Omodeo-Zorini; L Vago; R Boldorini; G Costanzi
Journal:  J Med Virol       Date:  1995-11       Impact factor: 2.327

Review 10.  New insights into progressive multifocal leukoencephalopathy.

Authors:  Igor J Koralnik
Journal:  Curr Opin Neurol       Date:  2004-06       Impact factor: 5.710

View more
  3 in total

1.  Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Authors:  J Kuhle; R Gosert; R Bühler; T Derfuss; R Sutter; O Yaldizli; E-W Radue; C Ryschkewitsch; E O Major; L Kappos; S Frank; H H Hirsch
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

Review 2.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

3.  Myelin basic protein-specific T lymphocytes proliferation and programmed cell death in demyelinating diseases.

Authors:  Marina Saresella; Ivana Marventano; Franca Rosa Guerini; Milena Zanzottera; Serena Delbue; Enrico Marchioni; Renato Maserati; Renato Longhi; Pasquale Ferrante; Mario Clerici
Journal:  Clin Immunol       Date:  2008-10-17       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.